Product for treating helicobacter pylori negative chronic atrophic gastritis accompanied by intestinal metaplasia and / or accompanied by dysplasia and preventing gastric cancer and treatment method thereof

The lotus leaf extract addresses the challenge of preventing gastric cancer progression in HP-negative patients by effectively treating atrophic gastritis and precancerous lesions, showing efficacy in inhibiting cell proliferation and reversing pathology in clinical trials.

CN119074747AInactive Publication Date: 2024-12-06TSINGHUA UNIVERSITY
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202411185749.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-27
Publication Date
2024-12-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

There is a lack of effective methods for preventing the progression of Helicobacter pylori-negative atrophic gastritis to gastric cancer, as HP eradication does not significantly reduce gastric cancer incidence, and current interventions are inadequate for HP-negative patients.

Method used

A lotus leaf extract containing isoquercetin, quercetin-3-O-glucoside, hyperoside, and nuciferine is used to treat Helicobacter pylori-negative chronic atrophic gastritis and gastric precancerous lesions, reversing pathology and preventing gastric cancer through a series of analyses, in vivo and in vitro experiments, and clinical trials.

Benefits of technology

The lotus leaf extract effectively inhibits malignant proliferation of gastric precancerous lesion cells, reduces reactive oxygen species, and reverses gastric precancerous lesions in mice, demonstrating significant pathological improvement in clinical trials, particularly in HP-negative patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_3
    Figure SMS_3
  • Figure SMS_4
    Figure SMS_4
Patent Text Reader

Abstract

The invention provides a product for treating helicobacter pylori negative chronic atrophic gastritis accompanied by intestinal metaplasia and / or accompanied by dysplasia, reversing pregastric cancer lesion pathology and preventing gastric cancer and a treatment method thereof. The representative active ingredients of the composition comprise, but are not limited to, isoquercitrin, quercetin-3-O-gluconic acid glycoside, hyperoside and nuciferine. The application comprises at least one of treatment of helicobacter pylori negative chronic atrophic gastritis accompanied by intestinal metaplasia and / or accompanied by dysplasia, reversal of precancerous lesions of gastric cancer and prevention of gastric cancer. In-vitro experiments show that the lotus leaf extract can inhibit malignant proliferation of gastric precancerous lesion epithelial cells and reduce the active oxygen level of the epithelial cells. In-vivo experiments show that the lotus leaf extract can effectively improve helicobacter pylori negative pregastric precancerous lesions and pathologies on an animal model and prevent the occurrence of gastric cancer. Clinical tests show that the lotus leaf extract can effectively treat pathology and symptoms of patients with helicobacter pylori negative chronic atrophic gastritis accompanied with intestinal metaplasia and / or atypical hyperplasia.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of traditional Chinese medicine, and in particular to a product and a treatment method thereof for treating Helicobacter pylori-negative chronic atrophic gastritis with intestinal metaplasia and / or with dysplasia, reversing gastric precancerous lesions, and preventing gastric cancer. Background Art

[0002] Gastric cancer is highly prevalent in my country. According to data from the National Cancer Center of China, "The Latest Current Status and Trends of Chinese Cancer in 2017", gastric cancer ranks second in the incidence of tumors in my country, and the number of new gastric cancer cases in my country each year accounts for about 43.9% of the world's total. The occurrence of gastric cancer is closely related to the malignant progression of gastritis. According to the classic Correa model, the occurrence of gastric cancer will go through a series of pathological states such as atrophic gastritis, intestinal metaplasia, and dysplasia (the latter two are called gastric precancerous lesions). Taking effective intervention and reversal measures against these pathological states is the key to the early prevention and control of gastric cancer.

[0003] At present, how to treat gastric precancerous lesions and block the progression of gastritis to gastric cancer is still a difficult problem in the prevention and treatment of gastric cancer. There is a lack of effective methods for the prevention and treatment of gastric cancer in Helicobacter pylori (HP)-negative patients. Clinically, the proportion of HP-positive patients is about 40%. Studies have shown that the eradication of HP is beneficial for the prevention of gastric cancer. A study published in the New England Journal of Medicine involving 1,676 subjects found that HP treatment can reduce the risk of cancer in subjects with a family history of gastric cancer [1]; however, a meta-analysis in the Journal of Gastroenterology found that the incidence of gastric cancer did not decrease significantly in the 10-year follow-up after HP eradication, which is consistent with the results of a clinical randomized controlled trial published in the Journal of the American Medical Association that HP eradication did not bring about a significant reduction in the incidence of gastric cancer [2, 3]. Expert consensus opinions such as the "Chinese Expert Consensus on Treatment Strategies for Gastric Mucosal Precancerous States and Lesions (2020)" also pointed out that the reversal effect of HP eradication on gastric precancerous lesions still needs further study [4]. Celecoxib was found to have an effect on the reversal of gastric precancerous lesions, but had no significant effect on patients after HP eradication [5]. Currently, intervention strategies for HP-negative atrophic gastritis mainly include lifestyle changes, gastric mucosal protective agents, and nonsteroidal anti-inflammatory drugs. There is no intervention drug that can improve pathology or reverse the transformation of gastritis to cancer. Therefore, how to prevent HP-negative or HP-eradicated atrophic gastritis patients from progressing to gastric cancer remains a major problem, and the discovery of new drugs is urgently needed [4-6].

[0004] Lotus leaf is the leaf of Nelumbo nuficera Gaertn, a plant of the Nymphaeaceae family. It is also known as lotus leaf and lotus leaf. It is grown in both northern and southern China. Compendium of Materia Medica and Essentials of Materia Medica record that lotus leaf has the effects of "generating vital energy, helping the spleen and stomach", "lightening the spleen, raising yang, and dispersing blood stasis".

[0005] The inventor's previous patent ZL201910849037.4 disclosed "the use of nuciferine and lotus leaf extract as a drug for the preparation of atrophic gastritis and / or blocking the transformation of gastritis into cancer", but did not clarify the difference in efficacy between Helicobacter pylori-negative and Helicobacter pylori-positive atrophic gastritis and gastric precancerous lesions, nor did it clarify the relevant active ingredient groups. This patent newly discovered the precise clinical positioning of lotus leaf extract in Helicobacter pylori-negative chronic atrophic gastritis with intestinal metaplasia and / or dysplasia, and reversal of gastric precancerous lesions, and revealed the representative active ingredient group of lotus leaf extract that exerts this effect. Summary of the invention

[0006] The present invention aims to solve at least one of the technical problems existing in the prior art to a certain extent. To this end, the present invention discloses a method and active ingredient group for treating Helicobacter pylori-negative chronic atrophic gastritis with intestinal metaplasia and / or with dysplasia, reversing gastric precancerous lesions, and preventing gastric cancer, and clarifies the clinical indications and intervention mechanisms, the treatment methods, and clinical research evidence.

[0007] The present invention provides a product and a treatment method thereof for treating Helicobacter pylori negative chronic atrophic gastritis with intestinal metaplasia and / or with dysplasia, reversing gastric precancerous lesions, and preventing gastric cancer, wherein the product is a lotus leaf extract. The Chinese medicine for food and medicine of the present invention is a lotus leaf extract, which has a stable preparation process, mature quality standards, good safety, and low cost.

[0008] In a first aspect of the present invention, the present invention provides a lotus leaf extract product, which, according to an embodiment of the present invention, is characterized in that it contains but is not limited to the following substances as representative active ingredients: isoquercetin, quercetin-3-O-glucoside, hyperoside and nuciferine.

[0009] In the second aspect of the present invention, the present invention proposes the use of lotus leaf extract in the preparation of medicines. According to an embodiment of the present invention, the lotus leaf extract includes but is not limited to the following substances as representative active ingredients: isoquercetin, quercetin-3-O-glucoside, hyperoside and nuciferine. The medicine is used to treat Helicobacter pylori-negative chronic atrophic gastritis with intestinal metaplasia and / or with dysplasia and / or for treating Helicobacter pylori-negative gastric precancerous lesions and / or for preventing gastric cancer.

[0010] The present invention determines the production process and quality standards, and further explores the application of lotus leaf extract in treating Helicobacter pylori-negative chronic atrophic gastritis with intestinal metaplasia and / or with dysplasia, reversing gastric precancerous lesions pathology, and preventing gastric cancer. The inventors determined the active ingredient group of lotus leaf extract in reversing Helicobacter pylori-negative gastric precancerous lesions through a series of analyses and experiments, verified the intervention mechanism and effect through in vivo and in vitro experiments, and determined its treatment method and clinical efficacy through rigorous real-world research and multi-center randomized double-blind placebo-controlled trials.

[0011] Wherein, the dosage form of the medicine or food is one selected from tablets, capsules, pills, injections, sustained-release preparations, controlled-release preparations, powders, beverages and the like.

[0012] Additional aspects and advantages of the present invention will be given in part in the following description and in part will be obvious from the following description, or will be learned through practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0013] The above and / or additional aspects and advantages of the present invention will become apparent and easily understood from the description of the embodiments in conjunction with the following drawings, in which:

[0014] Figure 1 The results of the experiment on the inhibition of malignant proliferation of Helicobacter pylori-negative gastric precancerous lesion epithelial cells by lotus leaf extract in Example 2 of the present invention are shown in Figure 2, wherein (A) is a graph showing the change in the proportion of Helicobacter pylori-negative gastric precancerous lesion epithelial cells at different lotus leaf extract intervention concentrations, and (B) is a graph showing the IC50 value of the inhibition of malignant proliferation of cells by lotus leaf extract;

[0015] Figure 2 The lotus leaf extracts prepared by different extraction processes in Example 3 of the present invention inhibit the malignant proliferation of Helicobacter pylori-negative gastric precancerous lesion epithelial cells, wherein (A) is a result diagram of the change of relative cell content under different lotus leaf extract concentrations treated by 20% ethanol extraction process, (B) is a result diagram of the change of relative cell content under different lotus leaf extract concentrations treated by 80% ethanol extraction process, (C) is a result diagram of the change of relative cell content under different lotus leaf extract concentrations treated by water extraction and alcohol precipitation supernatant, and (D) is a result diagram of the change of relative cell content under different lotus leaf extract concentrations treated by water extraction and alcohol precipitation precipitation;

[0016] Figure 3 The results of the study on the effect of lotus leaf extract on the reactive oxygen species (ROS) level in gastric precancerous lesion cells in Example 4 of the present invention are shown in Figure (A) as the percentage of the effect of the model group / lotus leaf extract group on gastric precancerous lesion cells (B525-A+ cells), and Figure (B) as the ROS cell ratio of the model group / lotus leaf extract group;

[0017] Figure 4 The results of the study on the efficacy of lotus leaf extract on Tff1-KO Helicobacter pylori negative gastric precancerous lesion model mice in Example 5 of the present invention are shown in Figure (A) which shows the proportion of mice in the model group / lotus leaf extract group / celecoxib group that progressed to severe dysplasia, and Figure (B) which shows the proportion of mice in the model group / lotus leaf extract group / celecoxib group that progressed to gastric cancer.

[0018] Figure 5 These are the results of the proportion of the cell dysplasia grades of mice in the model group / lotus leaf extract group / celecoxib group in Example 5 of the present invention. DETAILED DESCRIPTION

[0019] The embodiments of the present invention are described in detail below. The embodiments described below are exemplary and are only used to explain the present invention, and should not be understood as limiting the present invention.

[0020] It should be noted that the terms "first" and "second" are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of the indicated technical features. Therefore, the features defined as "first" and "second" may explicitly or implicitly include one or more of the features. Further, in the description of the present invention, unless otherwise specified, the meaning of "plurality" is two or more.

[0021] The endpoints and any values ​​of the ranges disclosed in this article are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of each range, the endpoint values ​​of each range and the individual point values, and the individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed in this article.

[0022] In this document, the terms “include” or “comprising” are open expressions, that is, including the contents specified in the present invention but not excluding other contents.

[0023] As used herein, the terms "optionally", "optional" or "optionally" generally mean that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.

[0024] product

[0025] The present invention provides a product for treating Helicobacter pylori negative chronic atrophic gastritis and / or gastric precancerous lesions and preventing gastric cancer, and the product is a lotus leaf extract. The Chinese medicine for food and medicine of the present invention is a lotus leaf extract, and its representative active ingredients include but are not limited to isoquercetin, quercetin-3-O-glucoside, hyperoside and nuciferine, and other excipients.

[0026] Wherein, the dosage form of the medicine or food is one selected from tablets, capsules, pills, injections, sustained-release preparations, controlled-release preparations, powders, beverages and the like.

[0027] use

[0028] The present invention proposes the use of lotus leaf extract in the preparation of medicines. According to an embodiment of the present invention, the lotus leaf extract includes but is not limited to the following substances as representative active ingredients: isoquercetin, quercetin-3-O-glucoside, hyperoside and nuciferine. The medicine is used to treat Helicobacter pylori-negative chronic atrophic gastritis with intestinal metaplasia and / or with dysplasia and / or for treating Helicobacter pylori-negative gastric precancerous lesions and / or for preventing the occurrence of gastric cancer. Specifically, the inventors determined the active ingredient group of lotus leaf extract that reverses gastric precancerous lesions through a series of analyses and experiments, and verified the intervention mechanism and effect through in vivo and in vitro experiments, compared the intervention of different preparation processes on gastric precancerous lesions, and determined its treatment method and clinical efficacy through rigorous real-world research and multi-center randomized double-blind placebo-controlled clinical trials.

[0029] In the process of carrying out and completing the present invention, the inventors conducted a series of experimental studies and clinical trials. The results of these experiments are given in the relevant description of the embodiments below. These experimental results show that lotus leaf extract can significantly treat Helicobacter pylori negative atrophic gastritis with intestinal metaplasia and / or with dysplasia, reverse gastric precancerous lesions, and prevent the occurrence of gastric cancer at a safe dose. In the above experiments, as well as in other work related to the present invention, the inventors' findings include:

[0030] (1) Study on the active ingredients of lotus leaf extract in the treatment of Helicobacter pylori-negative atrophic gastritis with intestinal metaplasia and / or dysplasia and reversal of gastric precancerous lesions

[0031] First, the production process standards are established and the preparation process is clarified. Then, the inventors constructed a method based on "network pharmacology prediction + multivariate experimental verification" to analyze the potential intervention targets and active ingredients of lotus leaf extract for the treatment of Helicobacter pylori-negative atrophic gastritis and reversal of gastric precancerous lesions. First, the network pharmacology method is used to analyze the potential intervention modules of the major components of lotus leaf extract for Helicobacter pylori-negative atrophic gastritis and gastric precancerous lesions at various stages from the perspective of biological function. Then, a cell-molecule-compound multilayer biological network is constructed to identify potential intervention targets and active ingredients, and the binding kinetics and binding affinity of lotus leaf extract components to target proteins are characterized by thermal proteomics and biomembrane interferometry technology, and potential active ingredients are experimentally verified from multiple angles.

[0032] (2) Lotus leaf extract inhibits the malignant proliferation of gastric precancerous epithelial cells

[0033] The human gastric epithelial cell GES-1 precancerous lesion model stimulated by chemical mutagen N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) was selected as the object, and the half inhibitory concentration (IC50) of lotus leaf extract on GES-1 gastric precancerous lesion model cells stimulated by MNNG was determined to be 537.8μg / mL. The results showed that lotus leaf extract can inhibit the proliferation of gastric precancerous lesion-related cells and block the transformation process of gastritis to cancer.

[0034] (3) Lotus leaf extract reduces the level of reactive oxygen species in gastric precancerous lesions

[0035] Using the MNNG-stimulated human gastric epithelial cell GES-1 precancerous lesion model as the subject, it was determined that lotus leaf extract reduced the proportion of cells with high reactive oxygen content in the GES-1 gastric precancerous lesion model cells stimulated by MNNG by 23%.

[0036] (4) Lotus leaf extract effectively reverses the pathology of gastric precancerous lesions in mice

[0037] The Tff1 knockout (Tff1-KO) mouse model, which has been shown in multiple studies to spontaneously develop various stages of gastritis and cancer, including atrophic gastritis, intestinal metaplasia, and dysplasia, was used as the subject. After the model was successfully established, celecoxib and lotus leaf extract were given by gavage. The pathological results showed that lotus leaf extract could effectively reverse the pathology of gastric precancerous lesions in mice.

[0038] (5) A real-world study and multicenter randomized double-blind placebo-controlled trial of lotus leaf extract in the treatment of Helicobacter pylori-negative atrophic gastritis with intestinal metaplasia and / or dysplasia and reversal of gastric precancerous lesions

[0039] Focusing on the clinical intervention efficacy of lotus leaf extract, a real-world effectiveness study of 138 cases and a multicenter randomized double-blind placebo-controlled trial of 200 cases were conducted. In the real-world study, patients who took lotus leaf extract for an average of 8 weeks (2-24 weeks) were the treatment group, and patients who did not take lotus leaf extract were the control group. The pathological improvement of the treatment group and the control group was analyzed. It was found that the pathological improvement of the treatment group was significantly better than that of the control group in the precancerous lesion stage (P<0.01), and the pathological improvement in the atrophy stage was also significantly better than that of the control group (P<0.05). It is worth noting that a subgroup analysis of the intervention group was conducted based on the Helicobacter pylori infection status, and it was found that the improvement rate of the Helicobacter pylori-negative group reached 37.0%, which was significantly higher than that of the Helicobacter pylori-positive group (Chi-Square test, P<0.05), suggesting that lotus leaf extract is expected to become the first drug to block or reverse the process of inflammatory cancer transformation in HP-negative patients. The randomized double-blind trial recruited patients with Helicobacter pylori-negative atrophic gastritis with intestinal metaplasia and / or dysplasia, and the pathological improvement rate of each patient after 6 months of medication was the primary outcome indicator. The results showed that at the baseline level, there was no significant difference in the pathological distribution between the lotus leaf extract group and the placebo group. At the 6-month follow-up point, the pathological improvement rates of the lotus leaf extract group and the placebo group in patients with Helicobacter pylori-negative precancerous lesions were 46.2% and 13.2%, respectively, with a statistically significant difference (P<0.01), which also provided clinical evidence for symptom improvement and provided data support for clarifying clinical positioning and further research.

[0040] The scheme of the present invention will be explained below in conjunction with the embodiments. It will be appreciated by those skilled in the art that the following embodiments are only used to illustrate the present invention and should not be considered as limiting the scope of the present invention. Where specific techniques or conditions are not indicated in the embodiments, the techniques or conditions described in the literature in this area or the product specifications are used. The reagents or instruments used are not indicated by the manufacturer and are all conventional products that can be obtained commercially.

[0041] Example 1: Study on the active components of lotus leaf extract in treating Helicobacter pylori-negative atrophic gastritis and / or reversing the pathological changes of gastric precancerous lesions

[0042] First, the preparation process of lotus leaf extract was established according to the quality standards published in the inventor's patent "A method for determining the content of active ingredients in lotus leaves and their preparations" (patent application number: 202410950437.5).

[0043] (1) Analysis of the mechanism of lotus leaf extract in intervening gastric precancerous lesions based on network pharmacology

[0044] Based on the UNIQ system (ZL201910902205.1) independently established by the inventors, the target spectrum of the components contained in the lotus leaf extract was predicted and calculated. The top 100 targets were selected as the candidate target set for each compound based on the accuracy of the algorithm. The reliability of the predicted targets of each compound was verified by the literature mining method. The recall rate of the predicted target set of each component in the literature reports was calculated.

[0045] Next, the overall target was enriched and analyzed. According to the gastritis-cancer transformation mechanism obtained in previous studies, the enrichment results were screened to obtain the potential pathways and biological processes of lotus leaf extract in intervening gastritis-cancer transformation. The pathway enrichment results are shown in Table 1. The analysis found that lotus leaf extract has an intervention effect on biological functions such as inflammation, immunity, lipid metabolism, oxidative phosphorylation, and cell proliferation in gastritis-cancer transformation.

[0046] Table 1: Pathway enrichment results

[0047]

[0048]

[0049] (2) Prediction of active ingredients in lotus leaf extract based on network targets

[0050] We further constructed a multi-level network of "component-molecule-cell" for lotus leaf extract to intervene in gastric precancerous lesions. In previous studies, three cell types most related to early gastric cancer cells were found, namely stemness-related MSC (intestinal stem cells), metabolism-related Enterocyte (intestinal cells) and proliferation-related PC (proliferating cells), revealing the important role of these three cells in the transformation of gastritis to cancer. Therefore, we compared and analyzed the predicted targets of lotus leaf extract with the characteristic genes of MSC, Enterocytes and PC, and constructed a component-molecule-cell network. This network contains compounds, genes, cells and the connections between them. In this network, cell characteristic genes predicted to be targets of at least one compound or adjacent to the predicted targets of at least one compound on PPI are displayed. Compounds are divided into different categories according to their chemical structures. In each category, compounds predicted to target more genes directly and indirectly (through PPI) are displayed in the network as representatives. A compound category is associated with a cell type if the compounds in the category are predicted to target more than 5 characteristic genes of the cell type. The lines between genes represent their direct connections in the protein-protein interaction network from the STRING database (V11.5).

[0051] Based on network pharmacology analysis, it was found that alkaloids, flavonoids and organic acid compounds in lotus leaves have a synergistic regulatory effect on immunity, inflammation, stemness, oxidative stress and lipid metabolism. Coumarin components have a more significant regulatory effect on immunity, lipid metabolism and oxidative stress, while lotus leaf polysaccharides have a more significant regulatory effect on immune inflammation, energy metabolism and oxidative stress.

[0052] Finally, based on component detection and network pharmacology analysis, we further analyzed which components in lotus leaf extracts may intervene in gastric precancerous lesions. First, we screened out compounds that could intervene in the characteristic genes of at least two types of cells, MSC, Enterocyte, and PC. Then, we performed functional analysis on the predicted target spectrum of each compound, focusing on the effects of the compounds on cell proliferation (including cell cycle, mitosis, etc.) and metabolic processes (including sugar metabolism, lipid metabolism, oxidative phosphorylation, etc.). We found that nuciferine in the alkaline components intervened in cell proliferation through HDAC2, YWHAQ, etc., and intervened in metabolic processes through APOB, ALDOA, etc.; N-nornusferine intervened in cell proliferation through HDAC2, CDKN2A, YWHAQ, etc., and intervened in metabolic processes through APOB, ALDOA, etc.; quercetin-3-O-β-D-glucuronide in flavonoids intervened in cell proliferation through CDK1, CDC20, BUB3, etc., and intervened in metabolic processes through OAT, IDH2, MTTP, etc., isoquercetin intervened in cell proliferation through PCNA, CDK1, CCND2, etc., and intervened in metabolic processes through FABP1, OAT, etc.; hyperoside and myricetin intervened in cell proliferation through PCNA, PLK1, HDAC2, etc., and intervened in metabolic processes through LDHA, LDHB, IMPDH2, APOA1, etc. In addition, these components can directly or indirectly intervene in key molecules in the P53 signaling pathway and TNF signaling pathway.

[0053] (4) Verification of the interaction between active ingredients and targets of lotus leaf extract

[0054] Experimental materials: nuciferine, isoquercetin, quercetin-3-O-glucuronide, rutin, hyperoside, NQO1-His, PRC1-His, and PRDX2-His.

[0055] Experimental method: The protein was diluted to 30-50 μg / mL and then fixed on the Ni-NTA sensor. The sensor was placed in a buffer containing different concentrations of the test compound, and the interaction between the protein and the test compound was detected using the ForteBio Octet Red96e molecular interaction analyzer. The binding signal was identified and analyzed using OctetHT V10.0 software, and KD (affinity) and R2 (an estimate of goodness of fit, close to 1 indicates a good fit) were calculated.

[0056] Experimental results: Combined with the results of network pharmacology analysis, targets such as PRC1, NQO1, and β-catenin, which play an important role in the gastritis-cancer transformation-related biological module, were selected for further study. The binding kinetics and binding affinity of lotus leaf components with target proteins were characterized using bio-layer interferometry (BLI) technology, and it was found that nuciferine and rutin in lotus leaf extracts bind to PRC1, hyperoside and rutin bind to NQO1, and isoquercetin and quercetin-3-O-glucuronide bind to β-catenin and other compound-target interactions. The KD and R2 values ​​are shown in Table 2.

[0057] Table 2: Results of lotus leaf extract component-target interaction

[0058] Compound protein KD R2 Nuciferine PRC1 491.2 0.971 Isoquercetin β-catenin 32.07 0.984 Quercetin-3-O-glucoside β-catenin 514.1 0.985 Hyperoside NQO1 88.32 0.972 Rutin NQO1 406.3 0.999 Rutin PRC1 41.01 0.949

[0059] The above results indicate that, combined with network pharmacology analysis, blood component analysis and component-target interaction verification analysis, isoquercetin, quercetin-3-O-glucoside, hyperoside and nuciferine were screened as the main representative active ingredients for intervening in gastritis-cancer transformation, which can be used as indicators for the preparation process design and quality control of lotus leaf extract.

[0060] Example 2: Experiment on the inhibition of malignant proliferation of Helicobacter pylori-negative gastric precancerous lesion epithelial cells by lotus leaf extract

[0061] Experimental materials: GES-1 cells, MNNG, lotus leaf extract, CCK-8 reagent.

[0062] Experimental method: GES-1 cells induced by MNNG were inoculated in 96-well plates and treated with equal volumes of water or different concentrations of lotus leaf extract for 24 hours. The cell proliferation rate was determined by CCK-8 reagent, and the cells were incubated at 37°C and 5% CO2 for 2 hours. The absorbance at 450nm was measured by microplate reader, and the curve was fitted and IC50 was calculated.

[0063] The results of the experimental study on the inhibition of malignant proliferation of Helicobacter pylori negative gastric precancerous lesion epithelial cells by lotus leaf extract are shown in Figure 1 .

[0064] Experimental results: Lotus leaf extract inhibited the proliferation of gastric precancerous lesion cells in a dose-dependent manner, IC50 = 537.8 μg / mL.

[0065] Example 3: Effects of lotus leaf extracts prepared by different extraction processes on inhibiting cell proliferation in gastric precancerous lesion model

[0066] Experimental materials: GES-1 cells, MNNG, lotus leaf extract, CCK-8 reagent.

[0067] Experimental method: Weigh 50 mg lotus leaf extracts from different processes, add 5 mL of enzyme-free sterile water, heat in a 60°C water bath with vortexing and ultrasonic dissolution, and filter through a 220 nm filter. MNNG-induced GES-1 cells (MNNG-GES-1) were plated in a 96-well plate. Different volumes of lotus leaf extract solutions were added to the experimental groups to concentrations of 100, 200, 400, 800, and 1600 μg / mL. After 24 hours of lotus leaf extract treatment, the cell number was detected by CCK-8 method, and the IC50 was calculated.

[0068] The effects of lotus leaf extracts prepared by different extraction processes on inhibiting cell proliferation in gastric precancerous lesion models are shown in Figure 2 .

[0069] Experimental results: The lotus leaf extracts prepared by different extraction processes all have an inhibitory effect on the proliferation of MNNG-GES-1 cells, and the inhibitory effect is concentration-dependent. The IC50 calculated for each group is shown in the following table. Combined with the results of Example 2, the IC50 of the lotus leaf extract obtained by the water extraction process is significantly lower than the IC50 of the lotus leaf extract obtained by 20% ethanol extraction, 80% ethanol extraction, water extraction and alcohol precipitation process, and water extraction and alcohol precipitation supernatant.

[0070] Table 3: Comparison of IC50 of lotus leaf extracts from different extraction processes

[0071] Extraction process <![CDATA[MNNG-GES-1IC 50 ]]> 20% ethanol extraction 744.0 μg / mL 80% ethanol extraction 953.2 μg / mL Water extraction and alcohol precipitation supernatant 1250 μg / mL Water extraction and alcohol precipitation 742.9 μg / mL

[0072] Example 4: Lotus leaf extract reduces the level of reactive oxygen species (ROS) in gastric precancerous lesion cells

[0073] Experimental materials: GES-1 cells, MNNG, lotus leaf extract, Hochest dye, DCFH-DA fluorescent probe.

[0074] Experimental methods:

[0075] (1) Cell culture and treatment: GES-1 cells induced by 20 μM MNNG were plated in 6-well plates and cultured for 24 h. The lotus leaf extract group was treated with 600 ng / mL lotus leaf extract for 10 h, while the model group was not treated.

[0076] (2) Probe incubation: Prepare working solution (1% Hochest, 0.05% DCFH-DA in 1640 culture medium), wash cells once with 1640 culture medium, add 1 mL of staining working solution and incubate in an incubator for 20 min, discard the working solution, wash cells three times with 1640 culture medium, collect cells, and perform flow cytometry detection.

[0077] The results of the study on the effect of lotus leaf extract on the level of reactive oxygen species (ROS) in gastric precancerous lesions are shown in Figure 3 .

[0078] Experimental results: Compared with the model group, lotus leaf extract intervention reduced the proportion of gastric precancerous lesion cells (B525-A+ cells) with high ROS from 78.8% to 60.5%, a decrease of 23%.

[0079] Example 5: Study on the efficacy of lotus leaf extract on Tff1-KO Helicobacter pylori negative gastric precancerous lesion model mice

[0080] Experimental methods:

[0081] (1) 12-month-old Tff1-KO Helicobacter pylori-negative mice were randomly divided into three groups: G1 (model group), G2 (lotus leaf extract group), and G3 (celecoxib group). There was no significant difference in the average body weight of each group of mice.

[0082] (2) The dosage was determined based on the previous rat dosage experiment, and the middle dose group with the best effect was selected and the dosage conversion formula for experimental animals was used.

[0083] (3) The administration time was the same as that of rats, which was 1 month. The rats were then killed after another 1 month.

[0084] (4) The evaluation indicators mainly consider the changes in mouse body weight and pathological results after intervention.

[0085] (5) According to the results of pathological interpretation, samples without gastric antrum and samples with poor quality were removed. The number of mice in each group was as follows: G1 (26 mice), G2 (16 mice), G3 (17 mice).

[0086] The results of the study on the efficacy of lotus leaf extract on Tff1-KO Helicobacter pylori negative gastric precancerous lesion model mice are shown in Figure 4 The results of the investigation on the proportion of dysplasia grade of mice in the model group / lotus leaf extract group / celecoxib group are shown in Figure 5 .

[0087] Experimental results: The lotus leaf extract group had a lower grade of dysplasia than the other groups. The incidence of canceration and severe dysplasia was 0, while the incidence of canceration and severe dysplasia in the model group was 38.1% and 11.5%, respectively; the incidence in the positive drug group was 33.3% and 11.8%. The results suggest that the lotus leaf extract group is significantly better than the model group and the positive drug group in treating Helicobacter pylori-negative gastric precancerous lesions and preventing gastric cancer.

[0088] Example 6: Real-world study and multicenter randomized double-blind placebo-controlled trial of lotus leaf extract in the treatment of Helicobacter pylori-negative atrophic gastritis and reversal of Helicobacter pylori-negative gastric precancerous lesions

[0089] For the clinical verification of the effectiveness and safety of lotus leaf extract in treating Helicobacter pylori-negative atrophic gastritis and reversing the pathological effectiveness of Helicobacter pylori-negative gastric precancerous lesions, a real-world effectiveness study of 138 cases and a multicenter randomized, double-blind, placebo-controlled trial of 200 cases were conducted.

[0090] 1. Real-world clinical trials of lotus leaf extract

[0091] A total of 138 patients were included in the real-world study. Among them, the lotus leaf extract treatment group included 46 patients who underwent endoscopy at the China-Japan Friendship Hospital and Yijishan Hospital of Anhui Wannan Medical College between May 2019 and December 2022, with an average baseline age of 57.35 years; including 17 males and 29 females; including 25 cases of chronic atrophic gastritis, 16 cases of intestinal metaplasia and 5 cases of low-grade dysplasia. Lotus leaf extract was taken for an average of 8 weeks. The control group samples were matched according to the propensity score matching method (ProPensity ScoreMethod). Age, gender and HP infection were selected as covariates, and the propensity score was calculated. The comprehensive propensity score was performed for the covariates through the Logistic regression model, and then the samples were matched according to the level of the score. After evaluating the matching results, the control group samples that were finally enrolled were determined. A total of 92 patients were included in the control group who did not take lotus leaf extract in this trial, with an average baseline age of 58.12 years; a total of 49 males and 47 females were included; the baseline of the control group included 48 patients with atrophy, 34 patients with intestinal metaplasia, and 10 patients with low-grade intraepithelial neoplasia. There was no significant difference in the above clinical indicators between the treatment group and the control group, ensuring the comparability of the intervention effect of lotus leaf extract.

[0092] According to the end-point pathological outcome of the patients, the pathological conditions of the patients in different groups at different stages were statistically analyzed to analyze the effect of lotus leaf extract on improving the pathology of patients with gastric precancerous lesions. The pathological progression was defined as the difference between the end-point pathological score and the baseline pathological score. If the score was less than 0, it indicated that the patient's pathology improved; if the score was 0, it indicated that the patient's pathology was maintained; if the score was greater than 0, it indicated that the patient's pathology worsened. At the baseline stage of intestinal metaplasia and low-grade intraepithelial neoplasia, the pathological improvement rate of the treatment group was 38.0%, and the improvement rate of the control group was 22.7%. According to the Chi-Square test, the pathological improvement of the patients in the treatment group was significantly better than that of the control group in the precancerous lesion stage (P<0.01). In the atrophic gastritis stage, the pathological improvement rate of the treatment group was 28%, and the improvement rate of the patients in the control group was 18.8%. According to the Chi-Square test, the pathological improvement of the patients in the treatment group in the atrophic stage was also significantly better than that of the control group (P<0.05).

[0093] It is worth noting that, as shown in Table 4, a subgroup analysis of the lotus leaf extract treatment group was conducted based on the status of Helicobacter pylori infection. It was found that the improvement rate of patients in the Helicobacter pylori-negative group was 37.0%, which was significantly higher than that in the Helicobacter pylori-positive group (Chi-Square test, P<0.05), suggesting that lotus leaf extract is expected to become the first drug to block or reverse the process of inflammatory-cancer transformation in HP-negative patients.

[0094] Table 4: Helicobacter pylori subgroup analysis of patients enrolled in the real-world study treated with lotus leaf extract

[0095]

[0096] 2. Randomized double-blind placebo-controlled clinical trial of lotus leaf extract

[0097] This study adopted a multicenter, randomized, double-blind, placebo-controlled parallel clinical trial design to study the intervention efficacy in patients with Helicobacter pylori-negative intestinal metaplasia and dysplasia.

[0098] Study population

[0099] (1) Selection criteria

[0100] 1) Aged between 18 and 70

[0101] 2) Endoscopic and pathological diagnosis of atrophic gastritis with intestinal metaplasia or dysplasia.

[0102] (2) Exclusion criteria

[0103] 1) Patients with a history of gastric ulcer, gastric polyps, gastroesophageal reflux disease, gastric surgery, or other digestive system diseases such as chronic liver disease;

[0104] 2) Those who have used glucocorticoids, nonsteroidal anti-inflammatory drugs and other drugs within three months;

[0105] 3) Those with clearly diagnosed serious primary diseases such as cardiovascular and cerebrovascular diseases, respiratory system, digestive system, endocrine system, etc., and whose condition has not been stabilized;

[0106] 4) Patients with severe liver or renal insufficiency (ALT or AST value greater than 2 times the upper limit of normal; serum creatinine value greater than 2 times the upper limit of normal);

[0107] 5) Those who are clearly allergic to lotus leaf-based foods or medicines;

[0108] 6) Pregnant or pregnant women, or breastfeeding women;

[0109] 7) Those who suffer from mental illness or other diseases that affect clinical evaluation or have difficulty cooperating with clinical investigations;

[0110] 8) Those suffering from tumors or other serious life-threatening diseases with an expected survival time of less than 12 months;

[0111] 9) Participating in other drug clinical trials within three months.

[0112] Sample size and randomization method

[0113] This study plans to include 200 subjects, using a block randomization method, with a 1:1 ratio between the experimental group and the control group (100 subjects in each group). Specialized statisticians will be responsible for generating random numbers and coding the test drugs and placebos according to the random numbers.

[0114] Trial Drugs

[0115] The test drug in this study was a lotus leaf extract preparation.

[0116] Treatment group: Based on the consensus opinions of TCM experts on chronic atrophic gastritis, pharmacopoeia specifications and other TCM intervention studies, the dosage regimen was 10g / bag, 1 bag / day, the course of treatment was 6 months, taken with water;

[0117] Control group: On the basis of conventional treatment, placebo was given as control drug, 10g per day. The shape, color and size of the placebo were similar to those of lotus leaf powder solid beverage;

[0118] Combined medication: During the study, under the guidance of professional clinical physicians, PPIs, H2 receptor antagonists, gastric mucosal protectors and other drugs can be used according to the condition of the disease, referring to the "Chinese Consensus on Chronic Gastritis (2017, Shanghai)". It is forbidden to take Chinese herbal preparations related to the treatment of gastric diseases (including Chinese herbal decoctions, Chinese patent medicines, etc.). The combined medication during the study period should be recorded truthfully in the CRF form.

[0119] End point index

[0120] (1) Primary endpoint

[0121] With reference to the Technical Guidelines for Clinical Efficacy Evaluation of New Chinese Medicines for Chronic Gastritis published in 2022 and the interpretation of relevant experts, gastric tissue samples were collected at baseline, 6 months and 12 months of follow-up, and the scores were scored according to the Correa pathological scoring system and the improvement rate was calculated. Two experienced pathologists scored each microscopic tissue according to the Sydney criteria for acute gastritis, chronic gastritis, atrophy, intestinal metaplasia, and dysplasia, with none (0), mild (1), moderate (2), and severe (3).

[0122] (2) Secondary endpoints

[0123] Improvement in Correa pathology score at 6 months.

[0124] Symptom improvement rate: The treatment method refers to the "Guidelines for Clinical Research of New Chinese Medicines". The typical symptoms of chronic gastritis and cold and heat syndrome are scored according to the frequency and severity of the symptoms. None (0), mild (1), moderate (2), severe (3).

[0125] Analyze the dataset

[0126] This trial has been registered in the Chinese Clinical Trial Register (ChiCTR), the primary registration institution of the World Health Organization's International Clinical Trial Registration Platform, with the registration number ChiCTR2000039549. All statistical analyses followed the principle of intention-to-treat. During the follow-up period, a total of 21 patients dropped out, of which 6 patients voluntarily withdrew their informed consent, and 15 patients were lost to follow-up due to factors such as the new crown and did not complete the outcome index examination. Baseline clinical characteristics and inter-group analysis were performed on 179 patients who met the protocol. There were no significant differences in baseline gender, age, ethnicity, pathological diagnosis, etc. between the lotus leaf extract and placebo groups, ensuring the comparability of the two groups in outcome indicators. In order to clarify the optimal clinical positioning of lotus leaf extract, subgroup analysis was carried out based on Helicobacter pylori infection, and the efficacy of 118 Helicobacter pylori-negative patients was compared.

[0127] Security Analysis

[0128] The safety evaluation indicators of this study include laboratory tests and adverse events. Laboratory tests include: blood routine: red blood cell count, hemoglobin, white blood cell count, neutrophil percentage, lymphocyte percentage, platelet count, etc.; blood biochemistry test: alanine aminotransferase, aspartate aminotransferase, creatinine, etc.; urine routine: red blood cells (high power field), white blood cells (high power field), protein, glucose, bacteria (high power field), occult blood, etc. Adverse events include serious adverse events (liver function, renal function damage, etc.), as well as other adverse events. In the first interim analysis, the laboratory test indicators of all enrolled patients were within the normal clinical reference range, the incidence of abnormal indicators was 0, and the incidence of all adverse events in the 6-month follow-up of the two groups was 0, and there was no obvious correlation with demographics or other baseline characteristics.

[0129] Efficacy analysis

[0130] The outcome indicators of 118 patients with negative Helicobacter pylori were analyzed. For the primary outcome indicators, the endoscopic pathological status (intestinal metaplasia and dysplasia) was recorded when the patients were enrolled, and endoscopic reexamination was performed after 6 months of continuous medication. The pathological status was statistically analyzed and the pathological status of the two endoscopic examinations was compared. The outcome indicators were defined as follows: improvement: the pathological status in 6 months was reduced compared with the baseline pathological score, such as the baseline intestinal metaplasia changed to atrophic gastritis, etc., maintenance: the pathological status in 6 months was consistent with the baseline pathology, such as intestinal metaplasia was still intestinal metaplasia, etc., progression: the pathological status in 6 months was aggravated compared with the baseline pathology, such as intestinal metaplasia changed to dysplasia, etc. The degree of improvement of the pathological status between different groups was determined, and the pathological changes between each group were statistically analyzed according to the baseline pathological status.

[0131] Table 5: Pathological outcomes of different groups of patients in RCT trials

[0132]

[0133]

[0134] The pathological improvement rate of each patient in the Helicobacter pylori negative group after 6 months of follow-up was calculated. The results showed that at the baseline level, there was no significant difference in the pathological distribution of the two groups of patients. At the 6-month follow-up point, the improvement rates of patients with intestinal metaplasia in the lotus leaf extract treatment group and the placebo group were 41.5% (22 / 53) and 15.5% (7 / 46), respectively, and the lotus leaf extract group was significantly better than the placebo group (Chi-Square test, P<0.01); while the improvement rates of patients with dysplasia in the two groups were 66.7% (8 / 12) and 0 (0 / 7), respectively, and the lotus leaf extract group was significantly better than the placebo group (Chi-Square test, P<0.01). In the precancerous lesion group with combined intestinal metaplasia and dysplasia, the pathological improvement rates of the two groups were 46.2% (30 / 65) and 13.2% (7 / 53), and the lotus leaf extract group was significantly better (Chi-Square test, P<0.01). Therefore, the lotus leaf extract of the present invention has significant clinical efficacy in treating Helicobacter pylori-negative chronic atrophic gastritis with intestinal metaplasia or dysplasia, providing data support for further research.

[0135] Furthermore, the improvement of symptoms in all 179 patients after 6 months of follow-up was evaluated. With reference to the "Guidelines for Clinical Research of New Chinese Medicines", typical symptoms such as chronic gastritis and cold and heat syndromes were scored according to the frequency and severity of the symptoms. There are four levels: none (0), mild (1), moderate (2), and severe (3). The statistical symptoms included: gastric bloating or fullness in the ribs, stomach pain, belching and acid reflux, loose stools, fatigue, bitter taste in the mouth, dry mouth, nausea and vomiting, refusal to press on the painful area, pain in a fixed area, loss of appetite, chest tightness, constipation, shortness of breath and laziness to speak, shortness of breath, vomiting of clear water, bland mouth, yellow urine, dry retching, dry stools, black stools, dark complexion, etc. Comparing the symptom scores at the 6-month follow-up time point with the baseline score, it was found that at the 6-month follow-up time point, among the five symptoms of gastric bloating, loss of appetite, heartburn, dry mouth and fatigue, the scores of the lotus leaf extract group were significantly improved (* indicates P < 0.01), and the symptom improvement scores were better than those of the placebo group (Wilcoxon test). Among the five groups of symptoms, the symptom improvement rates were: bloating: 17.9% in the placebo group and 52.3% in the lotus leaf extract group; loss of appetite: 7.7% in the placebo group and 13.6% in the lotus leaf extract group; heartburn: 5.1% in the placebo group and 31.8% in the lotus leaf extract group; dry mouth: 2.6% in the placebo group and 20.5% in the lotus leaf extract group; fatigue: 15.4% in the placebo group and 20.5% in the lotus leaf extract group. The improvement rates of each group in the lotus leaf extract group were significantly better than those in the placebo group (Chi-Square test, P<0.01).

[0136] Table 6: Improvement in symptom scores of patients in RCT trials

[0137]

[0138]

[0139] The experimental results of the above embodiments comprehensively show that the lotus leaf extract prepared by the production process and active ingredients proposed in the present invention can effectively treat Helicobacter pylori-negative chronic atrophic gastritis with intestinal metaplasia and / or dysplasia, reverse the pathology of gastric precancerous lesions, and prevent the occurrence of gastric cancer.

[0140] The examples given in the invention are not intended to limit the implementation methods of the invention. For ordinary technicians in the relevant field, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here, and the obvious changes or modifications derived from them are still within the scope of protection of the invention. It can be understood that the above embodiments are exemplary and cannot be understood as limitations of the invention. Ordinary technicians in this field can change, modify, replace and modify the above embodiments within the scope of the invention.

[0141] References

[0142] [1]Choi IJ, Kim CG, Lee JY, et al. Family History of Gastric Cancer and Helicobacter pylori Treatment. N Engl J Med. 2020; 382(5): 427-436.

[0143] [2] Ford AC, Yuan Y, Moayyedi P. Long-Term Impact of Helicobacter pyloriEradication Therapy on Gastric Cancer Incidence and Mortality in HealthyInfected Individuals: AMeta-Analysis Beyond 10 Years of Follow-Up. Gastroenterology. 2022; 163(3):754-756.e1.

[0144] [3]Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA. 2004; 291 (2): 187-194.

[0145] [4]Wong BC, Zhang L, Ma JL, et al. Effects of selective COX-2inhibitorand Helicobacter pylori eradication on precancerous gastric lesions. Gut. 2012; 61(6):812-818.

[0146] [5] National Clinical Research Center for Digestive Diseases (Shanghai), National Alliance of Early Digestive Cancer Prevention and Control Centers, Helicobacter pylori Group of the Chinese Society of Gastroenterology, et al. Expert consensus on the management strategies of gastric mucosal precancerous conditions and precancerous lesions in China (2020). Chinese Journal of Digestion, 2020, 40(11):11.

[0147] [6]Dinis-Ribeiro,M.,Shah,S.,El-Serag,H.,Banks,M.,Uedo,N.,Tajiri,H.,Coelho,LG,Libanio,D.,Lah ner,E.,Rollan,A.,Fang,JY,Moreira,L.,Bornschein,J.,Malfertheiner,P.,Kuipers,EJ,&El-Omar,EMThe road to a world-unified approach to the management of patients with gastric intestinal metaplasia: a review of current guidelines. Gut, 2024; gutjnl-2024-333029.

Claims

1. A lotus leaf extract product, characterized in that: The lotus leaf extract includes but is not limited to the following substances as representative active ingredients: isoquercetin, quercetin-3-O-glucoside, hyperoside and nuciferine.

2. The product according to claim 1, characterized in that The product is used to treat Helicobacter pylori-negative chronic atrophic gastritis with intestinal metaplasia and / or dysplasia.

3. The product according to claim 1, characterized in that The product is used to treat Helicobacter pylori-negative gastric precancerous lesions.

4. The product according to claim 1, characterized in that The product is used to prevent gastric cancer.

5. The product according to any one of claims 1 to 4, characterized in that: The product is one of a medicine and a food, wherein the dosage form of the medicine is selected from one of tablets, capsules, pills, injections, sustained-release agents, and controlled-release agents, and the product form of the food is selected from one of powders and beverages.

6. The product according to claim 5, characterized in that The product further contains pharmaceutically or food-acceptable excipients.

7. Use of lotus leaf extract in preparing medicine, characterized in that: The lotus leaf extract includes but is not limited to the following substances as representative active ingredients: isoquercetin, quercetin-3-O-glucoside, hyperoside and nuciferine. The drug is used to treat Helicobacter pylori-negative chronic atrophic gastritis with intestinal metaplasia and / or with dysplasia and / or to treat Helicobacter pylori-negative gastric precancerous lesions and / or to prevent the occurrence of gastric cancer.

Citation Information

Patent Citations

  • Application of lotus leaf alkaloids and lotus leaf extracts in the preparation of drugs for treating atrophic gastritis and / or blocking the transformation of gastritis into cancer.

    CN110393715B

  • Application of nuciferine and lotus leaf extract for preparing drug for treating atrophic gastritis and / or blocking transformation of gastritis cancer

    CN110123815A

  • Application of nuciferine and lotus leaf extract in preparation of drug for treating atrophic gastritis and / or blocking gastritis cancer conversion

    CN110393715A

  • Drug network pharmacology intelligent and quantitative analysis method and system based on network target

    CN110648726A

  • Lotus leaf powder solid beverage and preparation method thereof

    CN115192634A